Abstract: A method of treating a skin wound in a subject by administering at least one inhibitor of C-C chemokine receptor type-3 (CCR3) and/or at least one inhibitor of a CCR3 ligand, thereby causing increased activity of keratinocytes adjacent the skin wound, wherein epithelialization of the skin wound is promoted, and wherein the increased activity of keratinocytes is at least one of (1) increased proliferation of the keratinocytes and (2) increased migration of the keratinocytes adjacent the skin wound. The skin wound may be a chronic wound or an acute wound for example. The inhibitor may be, for example, an antibody or antibody fragment, a small molecule, or an siRNA able to inhibit expression of CCR3.

Abstract: A method of treating a skin wound in a subject by administering at least one inhibitor of C-C chemokine receptor type-3 (CCR3) and/or at least one inhibitor of a CCR3 ligand, thereby causing increased activity of keratinocytes adjacent the skin wound, wherein epithelialization of the skin wound is promoted, and wherein the increased activity of keratinocytes is at least one of (1) increased proliferation of the keratinocytes and (2) increased migration of the keratinocytes adjacent the skin wound. The skin wound may be a chronic wound or an acute wound for example. The inhibitor may be, for example, an antibody or antibody fragment, a small molecule, or an siRNA able to inhibit expression of CCR3.